Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06585943

I-Score: Intensive Stroke Cycling for Optimal Recovery and Economic Value

Traditional rehabilitation approaches are time and personnel intensive and costly, and leave ~75% of stroke survivors with residual disability. We propose a clinical trial to determine effects of forced aerobic exercise (FE; i.e., mechanically supplemented) in facilitating upper and lower extremity motor recovery post-stroke in an outpatient rehabilitation setting, to elucidate neural and biochemical substrates of FE-induced motor recovery, and to evaluate cost effectiveness of a FE-centered intervention compared to traditional stroke rehabilitation. The global effect of FE has the potential to enhance recovery in a growing population of stroke survivors in a cost-effective manner, thus accelerating its clinical acceptance.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Cleveland Clinic

Cleveland, Ohio, 44195, United States

Location status: Recruiting

Location contact

Courtney R Miller, DPT

CONTACT

[email protected]

216-509-7012

Donayja Harris, BS

CONTACT

[email protected]

Susan M Linder, DPT, PhD

PRINCIPAL_INVESTIGATOR

About this study

Traditional rehabilitation approaches following stroke involve 1:1 motor learning-based training to facilitate recovery of upper extremity (UE) and lower extremity (LE) function. These time- and personnel-intensive approaches are costly, yet leave ~75% of stroke survivors with residual disability. More effective alternative approaches to facilitate motor recovery following stroke have not been adopted clinically due to excessive time and cost. To advance clinical care, both effectiveness and cost of a candidate intervention must be considered simultaneously. Aerobic exercise (AE) is known to improve cardiovascular function following stroke and central nervous system (CNS) function in older adults and neurological populations. Strong theoretical arguments suggest that AE may facilitate motor recovery following stroke. A protocol that rigorously tests this theory in the subacute stroke population is warranted. Animal studies, coupled with our preliminary data, indicate a specific type of exercise - forced aerobic exercise (FE), where volitional movements are mechanically supplemented - improves motor recovery following stroke. The mechanical assistance provided by FE enables patients to achieve a more rapid and consistent exercise pattern beyond their volitional capabilities while maintaining their aerobic effort within a beneficial range. In our initial studies, persons completing FE cycling followed by a reduced dose of UE motor task practice exhibited greater recovery of UE motor function compared to those completing unassisted AE and motor task practice or extended sessions of motor task practice alone. Animal studies have shown that FE triggers the release of brain-derived neurotrophic factor (BDNF) and insulin-like growth factor-1 (IGF-1), thought to be critical building blocks for neuroplasticity. Project Hypothesis: FE facilitates high-intensity AE, which triggers growth factors essential for neuroplasticity, thereby 'priming' the CNS to facilitate motor recovery associated with motor retraining therapies. We propose a prospective, pragmatic clinical trial to determine effects of FE in facilitating UE and LE motor recovery post-stroke in an outpatient rehabilitation setting, to elucidate neural and biochemical substrates of FE-induced motor recovery, and to evaluate cost effectiveness of a FE-centered intervention compared to traditional stroke rehabilitation.

Aim 1: Determine effects of FE+rehab vs. time-matched rehab on the recovery of UE motor function.

Aim 2: Determine effects of FE+rehab vs. time-matched rehab on recovery of lower extremity motor function.

Aim 3: Determine effects of FE+rehab vs. rehab on electrophysiological and biochemical markers of neuroplasticity.

Aim 4: Evaluate cost-effectiveness of FE+rehab vs. rehab. The global effect of FE has the potential to enhance recovery in a growing population of stroke survivors in a cost-effective manner, thus accelerating its clinical acceptance. Our mechanistic aim will elucidate the effects of each approach on substrates underlying neuroplasticity.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Sixty-six individuals with chronic stroke able to provide informed consent who meet the following criteria for inclusion will be recruited from the Cleveland Clinic:

  • 3-9 months following single ischemic or hemorrhagic stroke confirmed with neuroimaging (ie: first-time stroke)
  • Fugl-Meyer motor score 19-55 in the involved UE
  • Fugl-Meyer score <34 in the involved LE demonstrating residual hemiparesis
  • Ambulatory ≥ 20 meters with no more than contact guard assistance
  • 18-85 years of age

Exclusion criteria

include:

  • hospitalization for myocardial infarction, heart failure or heart surgery within 3 months
  • cardiac arrhythmia
  • hypertrophic cardiomyopathy
  • history of multiple strokes
  • actively undergoing physical or occupational therapy or enrolled in another interventional study
  • severe aortic stenosis
  • untreated deep vein thrombosis or pulmonary embolus
  • unstable angina
  • uncontrolled hypertension
  • implanted pacemaker or defibrillator
  • dyspnea at rest
  • clinically significant neurologic condition/diagnosis other than stroke
  • recent history of elicit drug or alcohol misuse or significant mental health illness
  • significant contractures
  • anti-spasticity injection within 3 months of enrollment
  • skull hardware (e.g. screws/plates) or prior craniotomies that could shunt current flow altering EEG measures
  • other contraindication to exercise or EEGs

Treatment and study plan

Forced Rate Exercise + Rehab

Behavioral

The FE+rehab group (N=33) will complete FE on the cycle designed to augment pedaling rate to >75 RPM. Target heart rate zone will be set to 60-80% of HR reserve. The session will consist of a 5-min warm-up, 35-min main exercise set, and 5-min cool down. Following FE, abbreviated sessions of motor learning-based training will be administered by a neurologic OT and PT experienced in stroke rehabilitation, with 30 min focused on restoration of UE function (OT) and 15 min focused on LE motor function/ gait training (PT).

Rehabilitation

Behavioral

The rehab group will receive consecutive, full-length sessions of motor learning-based training, administered by a neurologic OT and PT experienced in stroke rehabilitation, with 45 min focused on restoration of UE function (OT) and 45 min focused on LE motor function/ gait training (PT).

Primary outcomes

  1. Upper Extremity Fugl-Meyer Motor Assessment

    Time frame: Baseline to end of treatment at 12 weeks and end of treatment + 6 months

    Impairment-based measure of the upper extremity post-stroke.

  2. Gait Velocity

    Time frame: Baseline to end of treatment at 12 weeks and end of treatment + 6 months

    Gait velocity obtained using motion capture.

  3. Plasma IGF-1

    Time frame: Before and after first and 24th treatment session

    Blood biomarker for neuroplasticity

  4. Serum BDNF

    Time frame: Before and after first and 24th treatment session

    Blood biomarker for neuroplasticity

  5. electroencephalograms

    Time frame: Baseline and end of treatment at 12 weeks

    Electroencephalograms will be obtained to determine the degree of active engagement of different cortical areas during active/passive UE and LE movements

  6. electroencephalograms

    Time frame: Baseline and end of treatment at 12 weeks

    Electroencephalograms will be obtained to determine the degree of active engagement of different cortical areas under each cycling condition

  7. electroencephalograms

    Time frame: Baseline and end of treatment at 12 weeks

    Electroencephalograms will be obtained to quantify inter-area communication and direction of information flow.

  8. Incremental cost-effectiveness ratio

    Time frame: baseline to end of treatment at 12 weeks and baseline to end of treatment + 6 months

    Incremental cost-effectiveness ratio (ICER) expressed as cost per quality of life years (QALY) will be computed using a healthcare perspective.

  9. Stroke Impact Scale

    Time frame: Baseline to end of treatment at 12 weeks and end of treatment + 6 months

    Self-reported quality of life measure, normalized to a score from 0-100 with higher scores indicative of better self-reported quality of life

Secondary outcomes

  1. Action Research Arm Test

    Time frame: Baseline to end of treatment at 12 weeks and end of treatment + 6 months

    Measure of upper extremity gross and fine motor function post-stroke

  2. Biomechanical Dexterity Task

    Time frame: Baseline to end of treatment at 12 weeks and end of treatment + 6 months

    Force tracking task - accuracy within targeted range

  3. Biomechanical measure of maximum grasp force

    Time frame: Baseline to end of treatment at 12 weeks and end of treatment + 6 months

    maximum grasp force measured with force transducer

  4. Bimanual Dexterity Task

    Time frame: Baseline to end of treatment at 12 weeks and end of treatment + 6 months

    Time to complete task when separating 2 force transducers

  5. Six minute walk test

    Time frame: Baseline to end of treatment at 12 weeks and end of treatment + 6 months

    Measure of walking capacity

  6. Lower Extremity Fugl-Meyer Motor Assessment

    Time frame: Baseline to end of treatment at 12 weeks and end of treatment + 6 months

    Impairment-based measure of the lower extremity post-stroke.

  7. Biomechanical Gait Analysis

    Time frame: Baseline, end of treatment at 12 weeks, end of treatment + 6 months

    Biomechanical assessment of the following spatio-temporal components of gait using motion capture: % of gait cycle spent in swing and stance phases, and in single and double limb support.

  8. Biomechanical Gait Analysis

    Time frame: Baseline, end of treatment at 12 weeks, end of treatment + 6 months

    Biomechanical assessment of gait cadence (steps/minute)

  9. Biomechanical Gait Analysis

    Time frame: Baseline, end of treatment at 12 weeks, end of treatment + 6 months

    Biomechanical assessment of stride length

  10. Biomechanical Gait Analysis

    Time frame: Baseline, end of treatment at 12 weeks, end of treatment + 6 months

    Biomechanical assessment of the following components of gait kinetics using motion capture: 1) peak anterior-posterior propulsion forces, 2) peak anterior-posterior braking forces, 3) peak vertical ground reaction forces, 4) peak lateral ground reaction forces.

  11. Biomechanical Gait Analysis

    Time frame: Baseline, end of treatment at 12 weeks, end of treatment + 6 months

    Biomechanical assessment of the following components of gait kinetics using motion capture: 1) total hip extension moment 2) total knee extension moment, 3) total ankle plantarflexion extension moment

  12. Biomechanical Gait Analysis

    Time frame: Baseline, end of treatment at 12 weeks, end of treatment + 6 months

    Biomechanical assessment of the following components of gait kinetics during stance phase using motion capture: 1) total hip extension power 2) total knee extension power, 3) total ankle plantarflexion extension power

  13. Biomechanical Gait Analysis

    Time frame: Baseline, end of treatment at 12 weeks, end of treatment + 6 months

    Biomechanical assessment of the following kinematic components of gait using motion capture: hip flexion/extension, knee flexion/extension, ankle plantar- and dorsi-flexion

  14. Plasma BDNF

    Time frame: Before and after first and 24th session

    Blood biomarker for neuroplasticity

  15. Somatosensory evoked potentials

    Time frame: Baseline

    lower extremity somatosensory evoked potentials

  16. Modified Rankin Scale

    Time frame: Baseline to end of treatment at 12 weeks and end of treatment + 6 months

    Measure of disability

  17. Peak oxygen consumption (Peak VO2)

    Time frame: Baseline to end of treatment at 12 weeks

    Measure of cardiorespiratory function

  18. Patient-Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) v 2.0 Physical Function

    Time frame: Baseline to end of treatment at 12 weeks and end of treatment + 6 months

    Self-reported quality of life measure of physical function computed as normalized T-scores (1-100 range), with higher scores indicative of greater self-reported quality of life

  19. Patient-Reported Outcomes Measurement Information System (PROMIS) Computerized Adaptive Test (CAT) v 2.0 Ability to Participate in Social Roles

    Time frame: Baseline to end of treatment at 12 weeks and end of treatment + 6 months

    Self-reported quality of life measure computed as a normalized T-score (0-100 range), with higher scores indicative of greater self-reported participation

Study contacts

Contact information is provided by the study sponsor or research team.

Courtney Miller, PT, DPT

CONTACT

[email protected]

216 509-7012

Donayja Harris, BS

CONTACT

[email protected]

216 445-2007

Sponsors and collaborators

Lead sponsor

The Cleveland Clinic

Other

Registry information

Official study title

The I-Score (Intensive Stroke Cycling for Optimal Recovery and Economic Value) Trial

Important dates

Study start
2024
Primary completion
2028
Study completion
2029
First posted
Sep 19, 2024
Registry last updated
Oct 16, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.